Japan Dry Eye Medication Market Insights Forecasts to 2033

• The Japan Dry Eye Medication Market Size was valued at USD 221.5 Million in 2023.
• The Market is growing at a CAGR of 4.84% from 2023 to 2033
• The Japan Dry Eye Medication Market Size is expected to reach USD 355.5 Million by 2033

The Japan Dry Eye Medication Market is anticipated to exceed USD 355.5 Million by 2033, growing at a CAGR of 4.84% from 2023 to 2033. The increasing occurrence of dry eye disease, advancement in pharmaceutical research (advanced drug delivery system), and support from healthcare policies & regulations, growing awareness about the condition are driving the growth of the dry eye medication market in the Japan.     

Market Overview

Dry eye treatment focuses on reversing or managing the condition or factor causing dry eyes. These medications include medicines to reduce inflammation, eye drops to control cornea inflammation, eye inserts that work like artificial tears, tear-stimulating medicines, blood serum drops, and nasal spray to increase tear production. Other procedures include the use of special contact lenses, unblocking oil glands, and use of light therapy and eyelid massage that help to treat severe dry eye conditions. Telemedicine and telehealth services, becoming increasingly popular, offer simpler ways to enhance patient outcomes. The increasing focus of physicians, surgeons, and other healthcare professionals for consultations to improve medication treatment for dry eye further upsurges the market growth. There are expanding opportunities in the market thanks to the expanding economies, professionals, and extensive healthcare infrastructure.

Report Coverage

This research report categorizes the market for the Japan dry eye medication market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Japan dry eye medication market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Japan dry eye medication market.

Driving Factors

Dry eye disease is prevalent among young and middle-aged Japanese office workers with more prevalent among females, CL wearers, and prolonged VDT users as per the survey conducted in Japan. The advanced ocular drug delivery system involves nanotechnology-based systems such as polymeric nanoparticles, solid lipid nanoparticles, nanostructured lipid carriers, and others are some of the advancements in pharmaceutical research that are driving the market growth for dry eye medication. Furthermore, the increasing awareness about dry eye disease along with its diagnosis and treatment by various government and non-government organizations are driving the market growth. In addition, the support from healthcare policies and regulations for the development of novel ocular drugs are promoting the market.

Restraining Factors

The population's use and adoption of dry eye medications are limited by severe laws pertaining to the medications that are available for therapy and long-term treatment plans, resulting in hampering the market. Further, the adverse effects associated with the medication limit the market growth.

Market Segmentation

The Japan Dry Eye Medication Market share is classified into disease type, dosage form, and distribution channel.

• The aqueous dry eye syndrome segment is dominating the Japan dry eye medication market during the forecast period.

The Japan dry eye medication market is segmented by disease type into evaporative dry eye syndrome and aqueous dry eye syndrome. Among these, the aqueous dry eye syndrome segment is dominating the Japan dry eye medication market during the forecast period. Aqueous dry eye is a classical dry eye disease condition in which the eyes do not produce enough tears. Aqueous dry eye syndrome is treated with artificial tears, medications like cyclosporine, and punctal plugs.

• The eye drops segment held the largest revenue share of the Japan dry eye medication market in 2023.

The Japan dry eye medication market is segmented by dosage form into gels, eye solutions, capsules & tablets, eye drops, and ointments. Among these, the eye drops segment held the largest revenue share of the Japan dry eye medication market in 2023. Lubricating eye drops, also called artificial tears help to relieve dry eye symptoms by maintaining the surface of the eye moist. The ease of usage and rise in patient compliance with the treatment are propelling the market.

• The retail pharmacies segment accounted for the largest market share in 2023.

Based on the distribution channel, the Japan dry eye medication market is divided into hospital pharmacies, retail pharmacies, and online pharmacies. Among these, the retail pharmacies segment accounted for the largest market share in 2023. The availability of pharmacists to help with dosing, customer service, and consultations is the factor responsible for driving the market in the retail pharmacies segment.   

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Japan dry eye medication market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• AbbVie GK
• Novartis Pharma K.K.
• Santen Pharmaceutical Co. Ltd.
• Janssen Pharmaceuticals Co. Ltd.
• Taisho Pharmaceutical Co. Ltd.
• Senju Pharmaceutical Co. Ltd.
• Otsuka Pharmaceutical Co. Ltd.
• Sun Pharma Japan Limited
• Kyowa Pharmaceutical Industry Co., Ltd.
• Asahi Kasei Pharma Corporation
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In February 2024, Nicox partners with Kowa to develop eye therapy in Japan. Kowa would pay €3m upfront and up to €27.5m in milestone-based payment to gain rights for Nicox’s intraocular pressure (IOP) reduction drug in Japan.

Market Segment

This study forecasts revenue at Japan, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the Japan Dry Eye Medication Market based on the below-mentioned segments:

Japan Dry Eye Medication Market, By Disease Type

• Evaporative Dry Eye Syndrome
• Aqueous Dry Eye Syndrome

Japan Dry Eye Medication Market, By Dosage Form

• Gels
• Eye Solutions
• Capsules & Tablets
• Eye Drops
• Ointments

Japan Dry Eye Medication Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies